SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and…

Artiva Biotherapeutics, Inc. · PRESS-RELEASE filed May 19, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 19, 2026 at 08:00 ET

Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles brings >20 years of drug development experience including FDA approvals (PREZISTA, INTELENCE) and leadership at J&J Innovation, Vividion, and Laronde. He has served on Artiva's board since May 2024. The appointment is accompanied by an inducement grant of 232,500 options + 77,500 RSUs. The company is advancing AlloNK in autoimmune diseases and preparing for a Phase 3 registrational trial in refractory RA, with FDA alignment on a registrational path and a planned BLA submission in 2029. This is a clinical-stage biotech ($228M market cap) with no approved products and minimal revenue, the hire adds credibility but does not change the fundamental risk profile.

  • Diego Miralles, M.D., appointed President and Head of R&D, effective May 18, 2026
  • Miralles has >20 years leadership experience across research, clinical development, commercialization, and company building
  • He was CEO of Laronde and Vividion, and Global Head of Johnson & Johnson Innovation
  • Miralles has served on Artiva's Board of Directors since May 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access